The scopolamine-reversal paradigm in rats and monkeys: The importance of computer-assisted operant-conditioning memory tasks for screening drug candidates

Psychopharmacology

Volumn 199, Issue 3, 2008, Pages 481-494

  Buccafusco, Jerry J ^a,b   Terry Jr , Alvin V ^a   Webster, Scott J ^a   Martin, Daniel ^a   Hohnadel, Elizabeth J ^a   Bouchard, Kristy A ^a   Warner, Samantha E ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cognition; Delayed matching; Donepezil; Monkeys; Scopolamine; Spatial memory

Indexed keywords

DONEPEZIL; SCOPOLAMINE;

ACCURACY; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; AUTOMATION; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; COMPUTER SYSTEM; DELAYED MATCHING TO SAMPLE TASK; DELAYED STIMULUS DISCRIMINATION TASK; HUMAN; INSTRUMENTAL CONDITIONING; MAZE TEST; MONKEY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SPATIAL MEMORY; TASK PERFORMANCE;

AGING; ANIMALS; CHOLINESTERASE INHIBITORS; COMPUTERS; CONDITIONING, OPERANT; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; INDANS; MACACA MULATTA; MALE; MAZE LEARNING; MEMORY; MUSCARINIC ANTAGONISTS; PIPERIDINES; PSYCHOMOTOR PERFORMANCE; RATS; RATS, LONG-EVANS; RATS, WISTAR; SCOPOLAMINE;

EID: 46649086754     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0887-8     Document Type: Article

References (55)

1. Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R (1992) Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 58:529-541
2. Bain JN, Prendergast MA, Terry AV Jr, Arneric SP, Smith MA, Buccafusco JJ (2003) Enhanced attention in Rhesus monkeys as a common factor for the cognitive effects of drugs with abuse potential. Psychopharmacology 169:150-160
3. Bartus RT (1978) Evidence for direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav 9:833-836
4. Bartus RT, Dean RL, Flicker C (1987) Cholinergic pharmacology: an integration of human and animal research on memory. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York, pp 219-232
5. Beglinger LJ, Tangphao-Daniels O, Karaken D, Zhang L, Mohs R, Siemers ER (2005) Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: a randomized controlled study. J Clin Psychopharmacol 25:159-165
6. Bejar C, Wang RH, Weinstock M (1999) Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur J Pharmacol 383:231-240
7. Berardi AM, Parasuraman R, Haxby JV (2005) Sustained attention in mild Alzheimer's disease. Dev Neuropsychol 28:507-537
8. Blackwell AD, Sahakian BJ, Vesey R, Semple J, Robbins TW, Hodges JR (2004) Detecting dementia: novel neuropsychological markers of preclinical AD. Dement Geriatr Cogn Disord 17:42-48
9. Buccafusco JJ, Terry AV Jr (2000) Multiple CNS targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther 295:438-446
10. Buccafusco JJ, Terry AV Jr (2004) Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys. J Molec Neurosci 24:85-91
11. Buccafusco JJ, Terry AV Jr, Murdoch PB (2002) A computer assisted cognitive test battery for aged monkeys. J Molec Neurosci 19:179-185
12. Buccafusco JJ, Jackson WJ, Stone JD, Terry AV Jr (2003) Sex dimorphisms in the cognitive-enhancing action of the Alzheimer's drug donepezil in aged rhesus monkeys. Neuropharmacology 44:381-389
13. Collie A, Maruff P (2000) The neuropsychology of preclinical AD and mild cognitive impairment. Neurosci Biobehav Rev 24:365-374
14. Collie A, Maruff P, Currie J (2002) Behavioral characterization of mild cognitive impairment. J Clin Exp Neuropsychol 24:720-733
15. de Bruin N, Pouzet B (2006) Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval. Pharmacol Biochem Behav 85:253-260
16. Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. Arch Neurol 30:113-121
17. Duka T, Ott H, Rohloff A, Voet B (1996) The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills. Psychopharmacology 123:361-373
18. Dunne MP, Hartley LR (1985) The effects of scopolamine upon verbal memory: evidence for an attentional hypothesis. Acta Psychol 58:205-217
19. Ebert U, Kirch W (1998) Scopolamine models of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest 28:944-949
20. Evans-Martin F, Terry Jr AV, Jackson WJ, Buccafusco JJ (2000) Evaluation of two rodent tasks: a method with retracting levers versus a method with closing doors. Physiol Behav 70:233-241
21. Hao J, Li K, Li K, Zhang D, Wang W, Yang Y, Yan B, Shan B, Zhou X (2005) Visual attention deficits in Alzheimer's disease: an fMRI study. Neurosci Lett 385:18-23
22. Heise GA (1984) Behavioral methods for measuring effects of drugs on learning and memory in animals. Med Res Rev 4:535-538
23. Jones RW, Wesnes KA, Kirby J (1991) Effects of NMDA modulation in scopolamine dementia. Ann NY Acad Sci 640:241-244
24. Koller G, Satzger W, Adam M, Wagner M, Kathmann N, Soyka M (2003) Effects of scopolamine on matching-to-sample paradigm and related testes in human subjects. Neuropsychobiology 48:87-94
25. Lieben CK, Blokland A, Sik A, Sung E, van Nieuwenhuizen P, Schreiber R (2005) The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology 30:2169-2179
26. Lindner MD, Hogan JB, Hodgers DB Jr, Orie AF, Chen P, Corsa JA, Leet JE, Gillman KW, Rose GM, Jones KM, Gribkoff VK (2006) Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping. Psycopharmacology 188:629-640
27. Lines CR, Ambrose JH, Heald A, Traub M (1993) A double-blind, placebo-controlled study of the effects of eptastigmine on scopolamine-induced cognitive deficits in healthy male subjects. Hum Psychopharmacol 8:271-278
28. Mewaldt SP, Ghoneim MW (1978) The effects and interactions of scopolamine, physostigmine and methamphetamine on human memory. Pharmacol Biochem Behav 10:205-210
29. Misane I, Ogren SO (2003) Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology 28:253-264
30. Molchan SE, Mellow AM, Lawlor BA, Weingartner HJ, Cohen RM, Cohen MR, Sunderland T (1990) TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 100:84-89
31. Paule MG, Bushnell PJ, Maurissen JPJ, Wenger GR, Buccafusco JJ, Chelonis JJ, Elliott R (1998) Symposium overview: the use of delayed matching-to-sample procedures in studies of short-term memory in animals and humans. Neurotoxicol Teratol 20:493-502
32. Prendergast MA, Jackson WJ, Terry AV Jr, Kille NJ, Arneric SP, Buccafusco JJ (1998) Age-related differences in distractibility and response to methylphenidate in monkeys. Cereb Cortex 8:164-172
33. Preston GC, Brazell C, Ward C, Broks P, Traub M, Stahl SM (1988) The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man. J Psychopharmacol 2:67-79
34. Preston GC, Ward C, Lines CR, Poppleton P, Haigh JR, Traub M (1989) Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine. Psychopharmacology 98:487-494
35. Ray PG, Meador KJ, Loring DW, Zamrini EW, Yang X-H, Buccafusco JJ (1992) Central anticholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol 5:72-77
36. Reidel W, Hogervorst E, Leboux R, Verhey F, van Praag H, Jolles J (1995) Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 122:158-168
37. Roman GC, Rogers SJ (2004) Donepezil: a clinical review of current and emerging indications. Expert Opin Pharmacother 5:161-180
38. Rossor M, Iversen LL (1986) Non-cholinergic neurotransmitter abnormalities in AD. Br Med Bull 42:70-74
39. Smith CM, Swash M (1978) Possible biochemical basis of memory disorder in AD. Ann Neurol 3:471-473
40. Snyder PJ, Bednar MM, Cromer JR, Maruff P (2005) Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. J Alzheimer's Dis Dement 1:126-135
41. Sunderland T, Weingartner H, Cohen RM, Tariot PN, Newhouse PA, Thompson KE, Lawlor BA, Mueller EA (1989) Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. Psychopharmacology 99:129-133
42. Taffe MA, Weed MR, Gold LH (1999) Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery. Cogn Brain Res 8:203-212
43. Takahata K, Minami A, Kusumoto H, Shimazu S, Yoneda F (2005) Effects of selegiline alone or with donepezil on memory impairment in rats. Eur J Pharmacol 518:140-144
44. Terry AV Jr, Buccafusco JJ, Jackson WJ, Zagrodnik S, Evans-Martin FF, Decker MW (1996) Effects of stimulation or blockade of central nicotinic-cholinergic receptors on performance of a novel version of the rat stimulus discrimination task. Psychopharmacology 123:172-181
45. Terry AV Jr, Buccafusco JJ, Decker MW (1997) Cholinergic channel activator, ABT-418, enhances delayed-response accuracy in rats. Drug Dev Res 40:304-312
46. Terry AV Jr, Gattu M, Buccafusco JJ, Sowell JW, Kosh JW (1999a) Ranitidine analog, JWS-USC-75IX, enhances memory-related task performance in rats. Drug Dev Res 47:97-106
47. Terry AV Jr, Buccafusco JJ, Prendergast MA (1999b) Dose-specific improvements in memory-related task performance by rats and aged monkeys administered the nicotinic-cholinergic antagonist mecamylamine. Drug Dev Res 47:127-136
48. Terry AV Jr, Buccafusco JJ, Prendergast MA (2003) The cholinergic hypothesis of AD: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306:821-827
49. Thompson S, Lanctot KL, Herrmann N (2004) The benefits and risks associated with cholinesterase inhibitor therapy in AD. Expert Opin Drug Saf 3:425-440
50. van der Staay FJ, Bouger PC (2005) Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats. Behav Brain Res 156:1-10
51. Van Dam D, De Deyn PP (2006) Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discovery 5:956-970
52. Van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, Schreiber R (2004) AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology 172:375-383
53. Wellstein A, Pitschner HF (1988) Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors. Naunyn-Schmiedebergs Arch Pharmakol 338:19-27
54. Wesnes K, Warburton DM (1984) Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 82:147-150
55. Youdim MBH, Buccafusco JJ (2005) CNS targets for multi-functional drugs in the treatment of neurodegenerative diseases. J Neural Transm 112:519-537